On May 23, 2023 Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported participation at the following investor events (Press release, Aadi Bioscience, MAY 23, 2023, View Source [SID1234631975]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s 4th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper) – The virtual event, taking place May 30 – 31, 2023, incorporates fireside chats hosted by members of TD Cowen research team that focus on various aspects of health care. Scott Giacobello, Interim CEO and President and CFO of Aadi, will participate in a fireside chat on Tuesday, May 30, 2023, at 11:30 am ET.
Jefferies Global Healthcare Conference – The conference will take place June 7-9, 2023, in New York City. Mr. Giacobello will participate in a fireside chat on Thursday, June 8, 2023, at 11:00 am ET. Company management will also participate in one-on-one meetings with investors during the conference.
The fireside chats will be webcast live on the IR pages of the Aadi Biosciences website and will be available for replay for approximately 30 days following each investor event.